OUR TEAM

While serving as the CFO of various life sciences companies, he successfully securing several major financing rounds, transforming companies from development stage to commercial organizations, and negotiating several transactions, including asset licensing deals and mergers and acquisitions.

Prior to joining Xenikos, Musial served as the Chief Financial Officer of several pharmaceutical and biotech companies, including EryDel SpA, Egalet, Inc. (which he took public on NASDAQ in 2014), Prism Pharmaceuticals, Inc. (acquired in 2011 by Baxter International), and Strategic Diagnostics, Inc. Musial received a BS in accounting from The Pennsylvania State University and his MBA from Temple University, and he is a Certified Public Accountant in the Commonwealth of Pennsylvania.

Prior to joining Xenikos in 2015, he held leading positions in quality affairs, business development, manufacturing, process development and project management in small biotechnology and large pharmaceutical firms. He shaped many biopharmaceutical product development initiatives from both a scientific and strategic business planning perspective. He made critical contributions to regulatory submissions for several innovative biopharmaceuticals and managed the corresponding pre-approval regulatory site inspections.

At Xenikos, Maarten is responsible for CMC development, manufacturing, logistics and related regulatory and quality assurance.

…for both new biological and new chemical entities, as well as in global clinical trial management and medical marketing.

Prior to joining Xenikos in 2016, Eric was Director Clinical Operations at Acerta-Pharma, where he was responsible for the set up and line management of the European clinical operations group, including the execution of Phase 1, 2 and 3 clinical trial programs with the compound acalabrutinib, a potential best-in-class irreversible oral Bruton’s tyrosine kinase (BTK) inhibitor, that contributed to a major transaction with AstraZeneca in December 2015. Eric previously worked as a Program Manager at Merck, where he managed Women’s Health Programs. He also worked at Organon for many years, in positions of increasing responsibility in both clinical development and medical marketing.

At Xenikos, Eric is responsible for the worldwide clinical development of T-Guard®.

…of skills that are well suited to the many aspects of her job at Xenikos – from data management, processing patient files, editing, writing and translating both scientific and non-scientific documents, to overseeing the administration, finances and daily agenda, HR, organizing meetings, and functioning as a contact person. She is currently also in training to become a Clinical Research Assistant (CRA).

Lisa studied history at Radboud University in Nijmegen, after which she moved to Antwerp, Belgium in 2015 to pursue a second degree in journalism at KU Leuven, specializing in both human-interest journalism and science journalism. She did an internship at National Geographic Magazine NL, where she researched and wrote about complex scientific issues.

…Synthon Biopharmaceuticals for almost 12 years, starting at the bioanalytical department in 2008. In 2009 she moved to the Downstream Process department, first as junior DSP researcher, and as senior DSP scientist from 2014 onwards.

During her time at Synthon, Maria has focused on the development of purification processes of monoclonal antibodies and ADC’s (from small to large scale), the planning of relevant CMC-related studies, writing specific project documentation, reviewing GMP-related documentation, and leading process scale up and technology transfer to the manufacturing plant, amongst others.

At Xenikos, Maria works as CMC Project Manager, and is responsible for managing the development, implementation and validation of biopharmaceutical manufacturing processes.

…knowledge in mammalian cell culture and fungal fermentation. He is a leader with a successful track record as a line manager, project manager, and subject matter expert in the mid-to-late-stage development and commercialization of biopharmaceuticals.

Prior to joining Xenikos in 2019, Jürgen was the Upstream Process Technology Lead at MSD Netherlands, where he managed a team of senior scientists in various programs focused on developing cell culture procedures for biotherapeutic proteins such as monoclonal antibodies (mAbs) and gonadotropins. Jürgen previously worked as a Product Steward at MSD and was responsible for providing global technical and scientific support of the upstream manufacturing of mAbs for Keytruda® (pembrolizumab), MSD’s immuno-oncology blockbuster. Prior to MSD, he worked at Organon in upstream process development.

At Xenikos, Jürgen is responsible for the development and commercialization of the manufacturing process for T-Guard® and other products.

…and team leader, with experience ranging from first-in-human studies through Phase 4 drug development for a broad range of therapeutic applications.

  Prior to joining Xenikos in 2020, Willem was the Head of Clinical Operations at Acerta Pharma BV, where he was responsible for the European Clinical Operations group and its expansion to include 18 full-time employees. Willem was also the Clinical Project Lead for several studies, including the acalabrutinib (Calquence®) ACE-LY-004 trial in mantle cell lymphoma, which led to the company’s first New Drug Application (NDA) approval and contributed to a major transaction with AstraZeneca in 2015.

  At Xenikos, Willem is responsible for overseeing clinical projects with T-Guard® in support of obtaining NDA approval for T-Guard.

…training at the Charité – Universitätsmedizin in Berlin, where she produced and purified recombinant proteins and active toxins using bacterial expression systems. Her thesis focused on developing a new recombinant drug by linking the toxin to a targeting ligand using either gene fusion technology or chemical coupling. Nicole joined Xenikos in early 2020 as a Bioanalytical Scientist, bringing her academic research expertise and experience, particularly in the field of drug development.

In her role as a Bioanalytical Scientist, Nicole is part of the CMC team and is primarily responsible for the development, implementation, and validation of analytical methods, as well as product characterization, managing the T-Guard stability program, and drafting and reviewing SOPs, protocols, reports, and studies.

…regulatory authority CBG (College ter Beoordeling van Geneesmiddelen, the Dutch Medicines Evaluation Board).

In the pharmaceutical industry, Sonja held several positions in analytical development (e.g., scientist, project manager, and scientific writer) and was involved in the development, commercialization, and post-marketing of biologics, with a focus on monoclonal antibodies. At CBG, she assessed all CMC-related sections of dossiers for biologics submitted to the board. Recently, Sonja worked as a CMC regulatory affairs consultant, where she defined regulatory strategies for clinical trial applications.

At Xenikos, Sonja is responsible for the CMC team’s regulatory affairs activities and supports analytical activities.

…several university hospitals in the UK and Germany. He received his training in hematology at the University of Cambridge and has an MD and PhD in clinical medicine. Hassan has more than 10 years of experience in clinical development, medical affairs, and pharmacovigilance at several leading pharma and biotech companies, including Anocca, AstraZeneca, and Boehringer Ingelheim. He has authored and co-authored more than 100 peer-reviewed publications and 70 abstracts for clinical and laboratory research regarding the biology and treatment of hematological malignancies. He is currently a member of the editorial and review boards of several hematology journals.

As Xenikos’ CMO, Hassan is responsible for overseeing the clinical development and Phase 3 testing of T-Guard for the treatment of SR-aGVHD.